Results 161 to 170 of about 51,591 (309)

Optimising cost-effectiveness of freedom from disease surveillance—Bluetongue Virus Serotype 8 as an example

open access: green, 2018
Simon R. Rüegg   +7 more
openalex   +1 more source

Will Extended‐Valency Pneumococcal Conjugate Vaccines Offer Enhanced Coverage Against Invasive Pneumococcal Disease for At‐Risk Children?

open access: yes
Acta Paediatrica, EarlyView.
Robert Cohen   +8 more
wiley   +1 more source

Final Analysis of the Phase 1/2 Trial of Valoctocogene Roxaparvovec for Severe Haemophilia A

open access: yesHaemophilia, EarlyView.
ABSTRACT Introduction Valoctocogene roxaparvovec is an adeno‐associated virus vector serotype 5 (AAV5)‐mediated gene therapy for severe haemophilia A (HA). Aim Report the final safety and efficacy results of the phase 1/2 trial of valoctocogene roxaparvovec. Methods An open‐label phase 1/2 trial (NCT02576795) enrolled adult males with severe HA (factor
Priyanka Raheja   +9 more
wiley   +1 more source

Considerations for the Use of AAV‐based Gene Therapy in HIV‐Positive Individuals With Haemophilia

open access: yesHaemophilia, EarlyView.
ABSTRACT Introduction There is a high prevalence of human immunodeficiency virus (HIV) infection among the haemophilia community due to treatment in the 1970s and 1980s with contaminated clotting factor. Lifelong treatment regimens for haemophilia and HIV are burdensome alone and pose a particular challenge for individuals living with both conditions ...
Jürgen K. Rockstroh   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy